- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-477/21: Action brought on 9 August 2021 — Glaxo Group v EUIPO — Cipla Europe (Shape of an inhaler)
ECLI:EU:UNKNOWN:62021TN0477
62021TN0477
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
EN
Official Journal of the European Union
C 382/34
(Case T-477/21)
(2021/C 382/47)
Language of the case: English
Parties
Applicant: Glaxo Group Ltd (Brentford, United Kingdom) (represented by: T. de Haan and F. Verhoestraete, lawyers)
Defendant: European Union Intellectual Property Office (EUIPO)
Other party to the proceedings before the Board of Appeal: Cipla Europe NV (Antwerp, Belgium)
Details of the proceedings before EUIPO
Proprietor of the trademark at issue: Applicant before the General Court
Trade mark at issue: European Union tridimensional mark (Shape of an inhaler) — European Union trade mark No 2 179 562
Procedure before EUIPO: Cancellation proceedings
Contested decision: Decision of the First Board of Appeal of EUIPO of 19 May 2021 in Case R 1835/2016-1
Form of order sought
The applicant claims that the Court should:
—set aside the contested decision;
—order EUIPO and the intervener to bear the costs, including those incurred by the applicant before the Office’s First Board of Appeal.
Pleas in law
—Infringement of Articles 94(1) of Regulation (EU) 2017/1001 of the European Parliament and of the Council and 41(2) of the Charter of Fundamental Rights of the EU;
—Infringement of Article 7(1)(b) of Council Regulation (EC) 40/94;
—Infringement of Article 52(2) of Council Regulation (EC) 207/2009.